WASHINGTON (AP) — U.S. health officials have allowed emergency use of the first antibody drug to help the immune system fight COVID-19, an experimental approach against the virus that has killed more than 238,000 Americans.
The Food and Drug Administration on Monday cleared the experimental drug from Eli Lilly for people 12 and older with mild or moderate COVID-19 not requiring hospitalization. It’s a one-time treatment given through an IV.
The therapy is still undergoing additional testing to establish its safety and effectiveness. It is similar to a treatment President Donald Trump received after contracting the virus last month.
Lilly’s studies of the antibody drug are continuing. Early results suggest it may help clear the coronavirus sooner and possibly cut hospitalizations in people with mild to moderate COVID-19. A study of it in hospitalized patients was stopped when independent monitors saw the drug did not seem to be helping in that situation.
The government previously reached an agreement to buy and supply much of the early production of Lilly’s drug.
One other treatment has an emergency use designation now — convalescent plasma, or the blood of COVID-19 survivors. No large studies have shown it to be more effective than usual care alone, however.
The new drug is part of an emerging family of biologic therapies that offer a promising new approach to preventing serious disease and death from COVID-19. Experts say the infused drugs could serve as a therapeutic bridge to help manage the virus until vaccines are widely available.
The drugs are laboratory-made versions of antibodies, blood proteins which the body creates to help target and eliminate foreign infections. The new therapies are concentrated versions of the antibodies that proved most effective against the virus in patient studies.
Regeneron Pharmaceuticals Inc. also has asked for emergency authorization for an antibody drug it is testing, the one Trump received.
FDA regulators authorized the Lilly drug using their emergency powers to quickly speed the availability of experimental drugs and other medical products during public health crises.
In normal times the FDA requires “substantial evidence” to show that a drug is safe and effective, usually through one or more large, rigorously controlled patient studies. But during public health emergencies the agency can lower those standards and require only that an experimental treatment’s potential benefits outweigh its risks.
The emergency authorization functions like a temporary approval for the duration of the COVID-19 pandemic. To win full approval, Lilly will have to submit additional research to fully define the drug’s safety and benefit for patients.
The government has signed an agreement with Lilly to spend $375 million to buy 300,000 vials of the drug. How many doses that would provide is unclear. Each vial contains 70 milligrams and that dose proved ineffective in the early results. It took four times that amount — 2,800 milligrams — to show any effect.
- Some patients diagnosed with COVID-19 may experience an odd symptom: rash-like inflammation of the toes.
- The Virginia Department of Health is reporting 1,477 new cases of COVID-19 on Saturday, with 91 new deaths. The state's positivity rate remains at 6.3%.
- Many Virginians are anxiously awaiting their chance to get the COVID-19 vaccine. The best way to ensure the state knows you want your shot is to pre-register on the Vaccinate Virginia website.
- Some Virginia residents are raising concerns about COVID-19 vaccination scheduling. They told 8News, they're worried that there could be a potential to miss an opportunity for an appointment, as the Department of Health is reaching out through unknown numbers.
- Some New York lawmakers are calling for Gov. Andrew Cuomo's impeachment after reports late Thursday that his top aides altered a state Health Department report to omit the true number of people killed by COVID-19 in the state's nursing homes.
- A total of 763,439 people have been fully vaccinated in Virginia. According to the most recent Census data, there are 8,535,519 people living in the state.
- Health experts are trying to determine how effective the COVID-19 vaccine is at stopping the spread of the virus.
- A family is grieving a loss as painful as it is surprising. They believe 48-year-old father Ben Price took his own life after developing a rare and little understood phenomenon called "COVID psychosis."
- The Crater Health District will now be holding COVID-19 vaccination clinics at Virginia State University. The first clinic will kick off at 9 a.m. on Saturday at the VSU Multi-Purpose Center.
- Some people are now scouring the internet on the hunt for vaccine events and possible extra doses. They then show up at local pharmacies hoping to score a shot.